GlassScriptPhysician profile
Mackenzie George
NPI 1750826061
$9,324.39
in general payments reported to CMS, 2019-2025
23 companies · $2,710 in 2025
The $2,710 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $571 · 2022: $1,125 · 2023: $1,892 · 2024: $3,027 · 2025: $2,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,709 · Consulting Fee: $1,550 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,708.96 |
| Consulting Fee | $1,550.00 |
| Education | $369.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,207.21 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,447.41 | 2021-2025 | |
| Lilly USA, LLC | $905.93 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $857.82 | 2024 | |
| Ucb, INC. | $824.31 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $745.56 | 2022-2025 | Sotyktu |
| Janssen Biotech, INC. | $695.17 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Amgen INC. | $617.89 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $338.62 | 2022-2025 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.32 | 2023-2025 | Spevigo |
| Incyte Corporation | $123.50 | 2022-2023 | Opzelura |
| Genzyme Corporation | $57.21 | 2024-2025 | |
| Biofrontera INC. | $52.69 | 2021-2022 | |
| Biowound Solutions, INC. | $37.77 | 2025 | Bio-Connekt |
| Integra Lifesciences Corporation | $35.95 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $32.73 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $30.06 | 2024-2025 | Nemluvio |
| Pfizer INC. | $28.79 | 2021-2022 | |
| Leo Pharma INC. | $28.18 | 2025 | Adbry |
| Genentech USA, INC. | $25.84 | 2025 | Xolair |
| Kyowa Kirin, INC. | $24.31 | 2025 | |
| Blueprint Medicines Corporation | $19.30 | 2025 | Ayvakit |
| Janssen Scientific Affairs, LLC | $9.82 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.